🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Recruitingn/aAges 18 Years - 80 YearsFemaleFujian Cancer Hospital
NCT06140589 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy. The clinicopathological data of patients with persistent, recurrent or metastatic cervical cancer treated with Cadonilimab were collected, and medical images (magnetic resonance, CT, etc.) before and after treatment were followed up, and the efficacy was evaluated according to RECIST standards. The incidence and severity of adverse events and clinically significant abnormal laboratory test results were collected to evaluate the safety of the drug. Survival benefit analysis

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * •Persistent, recurrent or metastatic cervical cancer; * The pathological types are squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma; * No combination with other multiple primary cancers; * MRI before treatment Or CT examination, according to RECIST evaluation standards, there is at least one measurable lesion; * ECOG score 0-1 points. * Subjects gave informed consent, voluntarily cooperated with clinical follow-up, and signed informed consent forms. Exclusion Criteria: * Patients with other histopathological types of cervical cancer, such as small cell carcinoma, clear cell carcinoma, sarcoma, etc.; * Previous treatment with immune checkpoint inhibitors; * There are drug contraindications, such as liver function Insufficiency, renal insufficiency, etc. * The patient withdraws the informed consent; * The researcher determines that the patient is not suitable to participate in this clinical study.
💊

What it tests

  • Cadonilimab
📍

Where

1 site
No. 420 Fuma Road, Jin'an District, Fuzhou City, Fujian Province
Fuzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy